Common pathological processes in Alzheimer disease and type 2 diabetes: A review

Li, Lin, Hölscher, Christian·2007·Brain Research Reviews
DOI 10.1016/j.brainresrev.2007.09.001

Cites (255)

Items 201–255 of 255

  1. Soluble beta-amyloid[25–35] reversibly impairs hippocampal synaptic plasticity and spatial learning
    Christian Hölscher, Simon Gengler, Victor A. Gault, Patrick Harriott, Hanspeter A. Mallot · 2007 · European Journal of Pharmacology
  2. Increased risk of Alzheimer's disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology?
    L. Jaap Kappelle, Geert Jan Biessels · 2005 · Biochemical Society Transactions
  3. Glucose-Induced Expression of the Cyclin-Dependent Protein Kinase 5 Activator p35 Involved in Alzheimer’s Disease Regulates Insulin Gene Transcription in Pancreatic β-Cells
    Mariano Ubeda, Daniel M. Kemp, Joel Francis Habener · 2004 · Endocrinology
  4. Glucose, insulin and the brain: modulation of cognition and synaptic plasticity in health and disease: a preface
    Geert Jan Biessels, Bert Bravenboer, Willem Hendrik Gispen · 2004 · European Journal of Pharmacology
  5. Glutamine Stimulates Argininosuccinate Synthetase Gene Expression through Cytosolic O-Glycosylation of Sp1 in Caco-2 Cells
    Carole Brasse‐Lagnel, Alain Fairand, Alain Lavoinne, Annie Husson · 2003 · Journal of Biological Chemistry
  6. Transforming growth factor-β protects human neurons against β-amyloid-induced injury
    Chun C. Chao, Shuxian Hu, Frederic H. Kravitz, Monica Tsang, W. R. Anderson, Phillip K. Peterson · 1994 · Molecular and Chemical Neuropathology
  7. Inhibition of l-type voltage dependent calcium channels causes impairment of long-term potentiation in the hippocampal CA1 region in vivo
    Darragh B. Freir, Caroline E. Herron · 2003 · Brain Research
  8. Insulin and cholesterol pathways in neuronal function, memory and neurodegeneration
    Daniel L. Alkon, Thomas J. Nelson · 2005 · Biochemical Society Transactions
  9. Metabotropic glutamate receptor activation and blockade: their role in long-term potentiation, learning and neurotoxicity
    Christian Hölscher, John Gigg, Shane M. O’Mara · 1999 · Neuroscience & Biobehavioral Reviews
  10. Oral Tolerance, Systemic Immunoregulation, and Autoimmunity
    Stephan Ströbel · 2002 · Annals of the New York Academy of Sciences
  11. Alternative routes for the formation of glyceraldehyde-derived AGEs (TAGE) in vivo
    Masayoshi Takeuchi, Sho‐ichi Yamagishi · 2004 · Medical Hypotheses
  12. Insulin Stimulates and Diabetes Inhibits O-Linked N-Acetylglucosamine Transferase and O-Glycosylation of Sp1
    Gipsy Majumdar, Jeremiah Wright, Paul Markowitz · 2004 · Diabetes
  13. Differential Effects of Diabetes on Adipocyte and Liver Phosphotyrosine and Phosphoserine Phosphatase Activities
    Najma Begum, Karl E. Sussman, Boris Draznin · 1991 · Diabetes
  14. Cerebral lesions in rats with streptozotocin-induced diabetes
    Noritsugu Mukai, Sadao Hori, Marsha E. Pomeroy · 1980 · Acta Neuropathologica
  15. Reduced O-glycosylated clathrin assembly protein AP180: implication for synaptic vesicle recycling dysfunction in Alzheimer's disease
    Pamela J. Yao, Paul D. Coleman · 1998 · Neuroscience Letters
  16. Post‐translational modification by O‐GlcNAc: Another way to change protein function
    Jeffrey E. Kudlow · 2006 · Journal of Cellular Biochemistry
  17. Risk factors for Azheimer’s disease during aging. Impacts of glucose/energy metabolism
    Hoyer, S. · 1998 · Journal of Neural Transmission. Supplementa
  18. Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products (AGEs) may be a promising biomarker for early detection of Alzheimer’s disease
    Sho‐ichi Yamagishi, Kazuo Nakamura, H. Inoue, Seiji Kikuchi, Masayoshi Takeuchi · 2005 · Medical Hypotheses
  19. Transforming Growth Factor-β in Human Diabetic Nephropathy
    Robyn G. Langham, Darren J. Kelly, Renae M. Gow · 2006 · Diabetes Care
  20. Links between Alzheimer's disease and diabetes
    Miao‐Kun Sun, Daniel L. Alkon · 2006 · Drugs of today
  21. Vasodilator responses to calcitonin gene-related peptide (CGRP) and amylin in the rat isolated perfused kidney are mediated via CGRP1 receptors.
    S Y Chin, Judith M. Hall, Susan Diana Brain · 1994 · Journal of Pharmacology and Experimental Therapeutics
  22. Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid
    BD Green, Victor A. Gault, Peter R. Flatt, Patrick Harriott, Brett Greer, Finbarr P.M. O'Harte · 2004 · Archives of Biochemistry and Biophysics
  23. Ataxin-10 Interacts with O-Linked β-N-Acetylglucosamine Transferase in the Brain
    Pia März, Jörg Stetefeld, Kerstin Bendfeldt, Cordula Nitsch, Jochen Reinstein, Robert L. Shoeman, Beatrice Dimitriades‐Schmutz, Martine Schwager, Dominic Leiser, Sabire Özcan et al. · 2006 · Journal of Biological Chemistry
  24. Overexpression of IRS2 in isolated pancreatic islets causes proliferation and protects human ?-cells from hyperglycemia-induced apoptosis
    Sonali Mohanty, Giatgen A. Spinas, Kathrin Maedler, Richard A. Zuellig, Roger Lehmann, Marc Yves Donath, Thomas Trüb, Markus Nießen · 2005 · Experimental Cell Research
  25. TGF- signaling is required for the function of insulin-reactive T regulatory cells
    Wei Du · 2006 · Journal of Clinical Investigation
  26. Amylin stimulates proximal tubular sodium transport and cell proliferation in the rat kidney
    Harris, P. J., Cooper, M. E., Hiranyachattada, S., Berka, J. L., Kelly, D. J., Nobes, M., Wookey, P. J. · 1997 · American Journal of Physiology-Renal Physiology
  27. Models of Alzheimer’s disease: cellular and molecular aspects
    Siegfried Hoyer · 1997 · Springer eBooks
  28. Probing the physicochemical and structural requirements for glycogen synthase kinase-3α inhibition: 2D-QSAR for 3-anilino-4-phenylmaleimides
    Prasanna Sivaprakasam, Aihua Xie, Robert J. Doerksen · 2006 · Bioorganic & Medicinal Chemistry
  29. Human Islet Amyloid Polypeptide Accumulates at Similar Sites in Islets of Transgenic Mice and Humans
    Eelco J.P. de Koning, Jo W.M. Höppener, J. Sjef Verbeek, Cor Oosterwijk, Karen L. van Hulst, Catherine A Baker, C.J.M. Lips, John F. Morris, Anne Clark · 1994 · Diabetes
  30. TRANSFORMING GROWTH FACTOR-??1 AND TUMOR GROWTH FACTOR-??-INDUCIBLE GENE-H3 IN NONRENAL TRANSPLANT CYCLOSPORINE NEPHROPATHY
    Robyn G. Langham, Melissa Egan, John P. Dowling · 2001 · Transplantation
  31. Gene expression alterations in brain areas of intracerebroventricular streptozotocin treated rat
    Edna Grünblatt, Eleni Koutsilieri, Siegfried Hoyer, Peter Franz Riederer · 2006 · Journal of Alzheimer s Disease
  32. Impairments of hippocampal synaptic plasticity induced by aggregated beta-amyloid (25–35) are dependent on stimulation-protocol and genetic background
    Simon Gengler, Victor A. Gault, Patrick Harriott, Christian Hölscher · 2006 · Experimental Brain Research
  33. Tumor necrosis factorα and insulin-like growth factor-I in the brain: Is the whole greater than the sum of its parts?
    Homer Venters, Suzanne R. Broussard, Jian-Hua Zhou, Rose-Marie Bluthé, Gregory G. Freund, Rodney W. Johnson, Robert Dantzer, Keith W. Kelley · 2001 · Journal of Neuroimmunology
  34. Insulin-secreting cells derived from stem cells: Clinical perspectives, hypes and hopes
    Enrique Roche, Juan Antonio Reig, Adolfo Campos, Beatriz Paredes, John Isaac, Susan M. L. Lim, Roy Calne, Bernat Soria · 2005 · Transplant Immunology
  35. Neuroprotective effect of TNFα against the β-amyloid neurotoxicity mediated by CDK5 kinase
    Daniel I. Orellana, Rodrigo A. Quintanilla, Ricardo Benjamin Maccioni · 2006 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
  36. Smoking increases serum levels of transforming growth factor-beta in diabetic patients.
    Enric Esmatjes, Lílliam Flores, Sergio Lario · 1999 · Diabetes Care
  37. Insulin differentially regulates protein phosphotyrosine phosphatase activity in rat hepatoma cells
    Joseph Meyerovitch, Jonathan Backer, Péter Csermely · 1992 · Biochemistry
  38. Role of transforming growth factor beta in diabetic nephropathy.
    Fuad N. Ziyadeh · 1994 · PubMed
  39. Protein Aggregation in Alzheimers Disease and Other Neoropathological Disorders
    Aristotelis C. Dimakopoulos · 2005 · Current Alzheimer Research
  40. Growth factors, cytokines, and renal fibrosis during the course of diabetic nephropathy.
    Jérôme Rossert, Catherine Terraz, Gaëlle Brideau · 2000 · PubMed
  41. Acetylcholine in human CSF: methodological considerations and levels in dementia of Alzheimer type
    Lutz Frölich, Albrecht Dirr, Mario E. Götz · 1998 · Journal of Neural Transmission
  42. Elevated serum triglycerides is the strongest single indicator for the presence of metabolic syndrome in patients with type 2 diabetes
    Maria Kompoti, Anargiros D. Mariolis, Alevizos Alevizos, Ioannis Kyriazis, Ioannis D. Protopsaltis, Eleni Dimou, Ioannis Lentzas, Dimitrios Levisianou, Afrodite Gova, Andreas I. Melidonis · 2006 · Cardiovascular Diabetology
  43. Transforming growth factor-beta 1 levels in women with prior history of gestational diabetes mellitus
    Serkan Yener, Tevfik Demir, Barış Akıncı, Fırat Bayraktar, Levent Kebapçılar, Mehmet Ali Özcan, S. Biberoǧlu, Sena Yeşil · 2006 · Diabetes Research and Clinical Practice
  44. Transforming growth factor β1 at clinical onset of Type 1 diabetes mellitus. A pilot study
    Lílliam Flores, S Näf, Rubén Hernáez · 2004 · Diabetic Medicine
  45. Role of TGFβ in Development of Spontaneous Autoimmune Thyroiditis in NOD.H-2h4 Mice
    Helen Braley‐Mullen, Kemin Chen, Yongzhong Wei · 2001 · The Journal of Immunology
  46. Cardiovascular risk in the spectrum of type 2 diabetes mellitus.
    Intekhab Ahmed, Barry J. Goldstein · 2006 · PubMed
  47. Is Glucagon-like peptide-1, an agent treating diabetes, a new hope for Alzheimer’s disease?
    Lin Li · 2007 · Neuroscience Bulletin
  48. Differential effects of diabetes on adipocyte and liver phosphotyrosine and phosphoserine phosphatase activities
    Najma Begum, K E Sussman, B. Draznin · 1991 · Diabetes
  49. Effects of long-term infusion of anorexic concentrations of islet amyloid polypeptide on neurotransmitters and neuropeptides in rat brain
    Urban Arnelo, Margery K. Herrington, Elvar Theodorsson, Thomas Edward Adrian, Roger D. Reidelberger, Jörgen Larsson, Jan Marcusson, Lisa Strömmer, Xianzhong Ding, Johan Permert · 2000 · Brain Research
  50. The aggravating role of the ubiquitin–proteasome system in neurodegenerative disease
    Chao-Chun Hung, Eleanor J. Davison, Philip A. Robinson · 2006 · Biochemical Society Transactions
  51. Altered immunoreactivity of islet amyloid polypeptide (IAPP) may reflect major modifications of the IAPP molecule in amyloidogenesis
    Zhi Ma, Gunilla Torstensdotter Westermark, Z.-C. Li, Ulla Engström, Per Westermark · 1997 · Diabetologia
  52. Introduction: Amyloid-Based Interventions in Alzheimer's Disease
    Gary J. Kennedy · 2007 · CNS Spectrums
  53. Human islet amyloid polypeptide accumulates at similar sites in islets of transgenic mice and humans
    Eelco J.P. de Koning, Jo W.M. Höppener, J. S. Verbeek · 1994 · Diabetes
  54. Managing Multiple Cardiovascular Risk Factors: State of the Science
    Jon H. Levine · 2006 · Journal of Clinical Hypertension
  55. Untitled work
    MP Mattson · 1999 · 10.1002/(sici)1097-4547(19991001)58:1